A common vitamin could help fight one of the deadliest brain cancers
A clinical trial is exploring whether high doses of vitamin B3 could give patients with glioblastoma a better chance against the aggressive brain cancer. Scientists found that niacin may help revive i
A clinical trial is exploring whether high doses of vitamin B3 could give patients with glioblastoma a better chance against the aggressive brain canc
Read Full Story at ScienceDaily →Why This Matters
Glioblastoma remains one of oncology’s most intractable challenges, with a median survival rate of just 12-15 months even after aggressive treatment. If vitamin B3—an affordable, widely available nutrient—can meaningfully extend survival or improve quality of life, it could disrupt a decades-long stagnation in brain cancer care, offering a rare glimmer of hope where few have existed.
Background Context
Niacin’s potential in oncology isn’t entirely novel—early 20th-century observations linked deficiencies to neurological decline—but its role in halting aggressive tumors has been largely overlooked until recently. Meanwhile, glioblastoma research has been dominated by high-cost immunotherapies and gene therapies, leaving patients with limited, often unsustainable options that strain healthcare systems.
What Happens Next
The trial’s results could pivot the conversation toward repurposing existing, low-cost compounds as adjunct therapies, potentially accelerating approvals if efficacy is demonstrated. Skeptics will scrutinize dosing levels and long-term side effects, while advocates may push for immediate integration into standard care protocols if data supports it.
Bigger Picture
This development aligns with a broader shift in oncology toward leveraging metabolic interventions, mirroring successes in other cancers where vitamins or repurposed drugs have shown promise. It also underscores the need for flexible regulatory pathways that can evaluate low-cost, scalable treatments alongside cutting-edge biologics.
